United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

18 Apr 2019
Change (% chg)

$-0.72 (-2.21%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ciechanover, Isaac 

Dr. Isaac E. Ciechanover, M.D. is the Chairman of the Board, President and Chief Executive Officer of the Company. He served as our President and Chief Executive Officer and a member of the Board since our founding in August 2012. From April 2010 to November 2012, Dr. Ciechanover was a partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where he primarily focused on life sciences investing. From 2004 to March 2010, he served in various capacities at Celgene Corporation, a biopharmaceutical company, most recently as Executive Director for Business Development. Dr. Ciechanover has also held business development and venture capital roles at pharmaceutical companies Amylin Pharmaceuticals and Pfizer and venture capital firm Pequot Ventures. Dr. Ciechanover received a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 882,883
Restricted Stock Award, USD 2,483,250
Long-Term Incentive Plans, USD --
All Other, USD 689
Fiscal Year Total, USD 3,366,820

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Isaac Ciechanover


Utpal Koppikar


Joseph Newell


Christopher Haqq


Mitchall Clark


Gad Soffer

As Of  31 Dec 2017